- Boehringer Ingelheim licensed a pre-clinical program from Kyowa Kirin.
- The program targets autoimmune diseases with a potential first-in-class small molecule.
- Kyowa Kirin may receive up to €640 million, including milestone payments and royalties.
Agreement Overview
Boehringer Ingelheim has acquired a pre-clinical program from Kyowa Kirin to develop a small molecule aimed at treating autoimmune diseases. This agreement grants Boehringer exclusive worldwide rights to the program.
Financial Terms
Kyowa Kirin is eligible to receive up to €640 million, which includes an upfront payment, success-based development, regulatory, and commercial milestone payments, along with royalties on potential sales.
Autoimmune Disease Challenge
Autoimmune diseases affect approximately one in ten people globally, posing a significant burden on patients and healthcare systems. Despite advancements, there remains a need for more effective and long-lasting treatments.
Development Potential
The licensed program aims to deliver a first-in-class treatment by targeting the root causes of autoimmune conditions. Boehringer Ingelheim, recognized for its expertise in autoimmune research, will leverage its capabilities to advance this innovation.
